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Closure System in Patients With a Stroke
and/or Transient Ischemic Attack Due to
Presumed Paradoxical Embolism Through
a Patent Foramen Ovale) Trial
Sammy Elmariah, MD, MPH,*y Anthony J. Furlan, MD,z Mark Reisman, MD,x David Burke, MD,y Moshe Vardi, MD,y
Neil J. Wimmer, MD,k Shuqiong Ling, MS,y Xiaohua Chen, MA,y David M. Kent, MD, MSC,{# Joseph Massaro, PHD,y**
Laura Mauri, MD, MSC,yk for the CLOSURE I InvestigatorsABSTRACTOBJECTIVES This study sought to identify predictors of recurrent ischemic neurologic events within the CLOSURE I
(Evaluation of the STARFlex Septal Closure System in Patients With a Stroke and/or Transient Ischemic Attack Due to
Presumed Paradoxical Embolism Through a Patent Foramen Ovale) trial.
BACKGROUND The CLOSURE I trial found that transcatheter patent foramen ovale (PFO) closure using the STARFlex
device was not superior to medical therapy in patients with cryptogenic stroke or transient ischemic attack (TIA) and PFO.
METHODS The CLOSURE I trial is a multicenter, randomized trial of transcatheter PFO closure compared with medical
therapy in patients who presented with cryptogenic stroke or TIA and had a PFO. We identiﬁed clinical predictors of
recurrent ischemic stroke or TIA during 2 years of follow-up using Cox proportional hazards regression within the pooled
intention-to-treat cohort.
RESULTS In 909 patients, the incidence of recurrent events was 5.7% with 25 patients suffering a recurrent stroke and
30 a TIA. Patients who had a recurrent event had higher body mass index (30.2  6.2 vs. 28.3  5.8%; p ¼ 0.03) and
more frequently had diabetes (19.2% vs. 7.1%; p ¼ 0.0016), hypertension (46.2% vs. 30.1%; p ¼ 0.015), and ischemic
heart disease (3.8% vs. 0.9%; p ¼ 0.05). Diabetes (hazard ratio [HR]: 3.39; 95% conﬁdence interval [CI]: 1.69 to 6.84;
p ¼ 0.0007), index TIA (HR vs. stroke: 2.13; 95% CI: 1.20 to 3.80; p ¼ 0.01), and the detection of atrial ﬁbrillation after
study enrollment (HR: 4.85; 95% CI: 2.05 to 11.47; p ¼ 0.0003) independently predicted recurrent ischemic neurologic
events. Recurrent neurologic events were more frequent in subjects with RoPE (Risk of Paradoxical Embolism) score #5
than those with >5 (14.5% vs. 4.2%; p < 0.0001).
CONCLUSIONS These ﬁndings suggest an alternative etiology to paradoxical embolism was frequently responsible for
recurrent events within the CLOSURE I trial. (Evaluation of the STARFlex Septal Closure System in Patients With a Stroke
or TIA Due to the Possible Passage of a Clot of Unknown Origin Through a Patent Foramen Ovale (PFO) [CLOSURE I];
NCT00201461) (J Am Coll Cardiol Intv 2014;7:913–20) © 2014 by the American College of Cardiology Foundation.
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914A s many as 40% of acute ischemicstrokes have no identiﬁable causeand are classiﬁed as cryptogenic
(1–3). Some cryptogenic strokes may be the
result of an embolus from the venous system
traversing a patent foramen ovale (PFO) into
the left-sided circulation, a phenomenon
known as a paradoxical embolism, but othermechanisms are likely responsible for neurologic
events in some patients. There have been many
studies demonstrating an association between PFO
and cryptogenic stroke (4–15), but this relationship
has not been consistent (16).
Among the difﬁculties in studying PFO closure for
the treatment of cryptogenic stroke is the fact that the
tackSEE PAGE 921presence of PFO does not ensure that a stroke, even
in the absence of an identiﬁable cause, is actually
the result of a paradoxical embolism. Previous in-
vestigators have coined the term “PFO propensity” as
the probability of ﬁnding a PFO in a patient with a
cryptogenic stroke on the basis of age and other risk
factors (17). Central to this idea is the understanding
that stroke is more prevalent with advancing age, as
are traditional stroke risk factors (18). Signiﬁcant
controversy remains about the optimal approach to
secondary stroke prevention in patients with PFO and
a cryptogenic stroke (19,20). Several observational
studies have suggested a potential beneﬁt to PFO
closure in patients with PFO and previous stroke
(21–30), but the results of the ﬁrst randomized clinical
trials comparing PFO closure in patients with cryp-
togenic stroke have failed to show a deﬁnitive beneﬁt
from the procedure (31–33).
The goal of this analysis is to identify risk factors
for the development of recurrent neurologic events in
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(Evaluation of the STARFlex Septal Closure System in
Patients with a Stroke and/or Transient Ischemic
Attack due to Presumed Paradoxical Embolism
through a Patent Foramen Ovale) trial.METHODS
STUDY DESIGN. Details of the study design and
overall results have been reported previously (31).
Brieﬂy, the CLOSURE I study was a prospective,
multicenter, randomized, open-label, 2-group supe-
riority trial, comparing transcatheter PFO closure to
medical therapy alone in patients between 18 and
60 years of age who presented with cryptogenic
stroke or TIA and had a PFO. The trial was sponsored
by NMT Medical, and the study protocol was designed
by the executive committee in consultation with the
U.S. Food and Drug Administration. Data were col-
lected and analyzed by the Harvard Clinical Research
Institute.
PATIENT POPULATION. Patients were eligible to
participate in the trial if they were between 18 and 60
years of age; presented with a deﬁnite, clinically
conﬁrmed TIA or ischemic stroke within the previous
6 months; and had evidence of a PFO by trans-
esophageal echocardiography with bubble study
showing right-to-left shunting during Valsalva ma-
neuver. Deﬁnite clinically conﬁrmed TIA was deﬁned
as a sudden, focal neurologic event lasting at least
10min without evidence of acute ischemic brain injury
on diffusion-weighted magnetic resonance imaging,
with symptoms consisting of hemiplegia/paresis,
monoplegia/paresis, quadriplegia/paresis, language
disturbance other than isolated slurred speech,
blindness in one or both eyes, or signiﬁcant difﬁculty
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915potential cause of the neurological event, other than
the PFO, was identiﬁed at the time of screening. Such
factors included clinically signiﬁcant carotid artery
disease, complex aortic arch atheroma, left ventricular
dysfunction or aneurysm, or atrial ﬁbrillation. All trial
participants provided written informed consent.
STUDY PROCEDURES AND ENDPOINTS. Eligible pa-
tients were randomly assigned in a 1:1 ratio to either
percutaneous PFO closure with medical therapy or
medical therapy alone. Patients assigned to closure
with the device underwent percutaneous closure of
the PFO using the STARFlex device (NMT Medical,
Boston, Massachusetts). After the procedure, all pa-
tients were given a standard antiplatelet regimen,
including clopidogrel, 75 mg daily for 6 months, and
aspirin, 81 or 325 mg daily for 2 years. Patients
assigned to medical therapy were treated with
warfarin (with a target international normalized ratio
of 2.0 to 3.0), aspirin (325 mg daily), or both, at the
discretion of the principal investigator at each site.
Clinical endpoint assessment was performed at
6, 12, and 24 months following initial randomization
by a board-certiﬁed neurologist. The primary
outcome for this analysis is recurrent neurologic
event (TIA or stroke) in the 2-year follow-up period
following randomization. A TIA was deﬁned as pre-
viously described. A neurologic event with positive
cardiac magnetic resonance imaging was considered a
stroke, regardless of duration of clinical symptoms.
An independent clinical events committee adjudi-
cated the study endpoints. Echocardiographic data
were analyzed by the Echo Core Lab of the University
of Pennsylvania Cardiac Care at Radnor.
RISK OF PARADOXICAL EMBOLISM SCORE. The
RoPE (Risk of Paradoxical Embolism) study is a retro-
spective study of 12 component databases of patients
with cryptogenic stroke (n ¼ 3,674) aimed at devel-
oping predictive models to identify those patients
most likely to beneﬁt from preventative treatments for
PFO-related stroke recurrence (34). The compiled data
were used to derive the RoPE score, which aims to
predict the likelihood of PFO in patients with crypto-
genic stroke with the premise that doing so identiﬁes
those patients in whom PFO likely mediated a cryp-
togenic stroke (35). The RoPE score is a 10-point index
that includes a subtracted point for each of 5 nonage
factors (diabetes, hypertension, smoking, previous
TIA or stroke, and presence of a cortical stroke on
neuroimaging) and for each full decade over age
20 years (up to 5 points). The prevalence of PFO and
PFO-attributable risk increases with increasing score.
For example, those with 0 to 3 points have a PFO
prevalence of 23% compared with 73% prevalence inthose with 9 or 10 points. Based on Bayes theorem and
assuming a PFO prevalence in the general population
ofw25%, the PFO-attributable risk increases from near
0 in those with lowest scores to w88% in those with
the highest score. Application of the score in 1,324
patients with follow-up data demonstrated that stroke
recurrence rates decrease as the RoPE score increases,
suggesting that patients with index events most likely
to be PFO-attributable are the least likely to experi-
ence recurrent ischemic events (35).
In the present analysis, we applied the RoPE score
to the CLOSURE I trial study population to assess the
estimated distribution of PFO-mediated index events.
We subsequently stratiﬁed recurrent neurologic
events by RoPE score to evaluate the relationship of
recurrent events to the likelihood that the index
event was PFO-related.
STATISTICAL ANALYSIS. Analyses were performed in
the intention-to-treat population, deﬁned as all pa-
tients randomly assigned to a treatment group (this
included both the closure group and the medical
therapy group). For the purposes of this analysis, the
population was pooled and considered independent of
treatment assignment within the trial. Poolability of
these data is supported by the comparable patient de-
mographics and major adverse event rates across
treatment arms. Descriptive statistics are shown for
demographics, comorbidities, and clinical character-
istics. Data are expressed asmean standard deviation
(SD) or proportions as appropriate. Univariable ana-
lyses of continuous variables were performed using a
2-sided unpaired Student t-test and categorical
variables were compared using the chi-square test.
Clinical predictors of recurrent ischemic stroke or TIA
were identiﬁed using univariable and multivariable
Cox proportional hazards regression modeling.
Candidate predictors included age, sex, body mass
index, diabetes mellitus, hypertension, ischemic heart
disease, cigarette smoking, type of index neurologic
event (TIA vs. stroke), and detection of atrial ﬁbrilla-
tion or ﬂutter (AF) after enrollment. Stepwise selection
was used to generate ﬁnal multivariable models with
p<0.20 used for entry and 0.05 for retention. A 2-sided
Cochran-Armitage trend test was used to test for trend.
A p value of < 0.05 was used to deﬁne statistical
signiﬁcance.RESULTS
PATIENT CHARACTERISTICS. A total of 909 patients
were included in this analysis, 447 of which under-
went PFO closure. There were 857 patients without a
subsequent neurological event. The 52 patients with a
TABLE 1 Baseline Patient Characteristics
No Recurrent
Neurologic Event
n ¼ 857
Recurrent
Neurologic Event
n ¼ 52 p Value
Age, yrs 45.9  9.4 47.1  9.2 0.36
Male 449 (52) 22 (42) 0.16
Race 0.09
American Indian/Alaskan 7 (1) 0 (0)
Asian 15 (2) 0 (0)
Black 39 (5) 6 (12)
Paciﬁc Islander 4 (0) 1 (2)
White 767 (90) 45 (87)
Other 25 (3) 0 (0)
Cigarette smoking 184 (22) 16 (31) 0.12
Mean blood pressure 91.9  10.6 93.1  11.6 0.45
BMI 28.3  5.8 30.2  6.2 0.030
Diabetes mellitus 61 (7) 10 (19) 0.0016
Hypertension 258 (30) 24 (46) 0.015
Hypercholesterolemia 377 (44) 24 (46) 0.76
Family history of CVD 478 (56) 26 (50) 0.42
Ischemic heart disease 8 (1) 2 (4) 0.05
Valvular dysfunction 87 (10) 7 (13) 0.45
Arrhythmia 43 (5) 2 (4) 0.71
Peripheral vascular disease 10 (1) 2 (4) 0.10
Pulmonary embolus 3 (0) 1 (2) 0.10
Migraine 273 (32) 22 (42) 0.12
Index event for study entry 0.018
Cryptogenic stroke 623 (73) 30 (58)
TIA 232 (27) 22 (42)
Values are mean  SD or n (%).
BMI ¼ body mass index; CVD ¼ cardiovascular disease; TIA ¼ transient ischemic attack.
FIGURE 1 Distribution of Recurrent Ischemic Neurologic Events by D
Distribution of recurrent ischemic neurologic events by decade of age.
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916recurrent neurological event suffered 25 cryptogenic
strokes and 30 TIA. Baseline characteristics, comor-
bidities, and neuroimaging results of the groups are
detailed in Table 1. Patients with subsequent neuro-
logical events had higher body mass index (30.2  6.2
vs. 28.3  5.8, p ¼ 0.03) and more prevalent diabetes
(19.2% vs. 7.1%; p ¼ 0.0016), hypertension (46.2% vs.
30.1%, p ¼ 0.015), and ischemic heart disease (3.8%
vs. 0.9%, p ¼ 0.05). With increasing decades of life, an
increasing proportion of patients suffered recurrent
neurologic events, although this pattern did not reach
statistical signiﬁcance (p ¼ 0.37, p trend ¼ 0.23)
(Fig. 1). AF was diagnosed after randomization more
frequently in those who suffered a recurrent neuro-
logic event than in those who did not (13.5% vs. 2.6%;
p < 0.0001).
PREDICTORS OF RECURRENT NEUROLOGICAL
EVENTS. Univariable Cox proportional hazards re-
gression identiﬁed baseline body mass index (hazard
ratio [HR]: 1.05, 95% conﬁdence interval [CI]: 1.00 to
1.09; p ¼ 0.03), history of diabetes (HR: 2.88, 95% CI:
1.45 to 5.74; p ¼ 0.0027), hypertension (HR: 1.92, 95%
CI: 1.11 to 3.31; p ¼ 0.02), ischemic heart disease (HR:
4.38, 95% CI: 1.07 to 18.01; p ¼ 0.04), and index TIA
(vs. stroke; HR: 1.98, 95% CI: 1.14 to 3.43; p ¼ 0.02) as
predictors of recurrent neurologic events (Table 2). In
addition, the detection of AF during follow-up por-
tended a markedly increased risk (HR: 4.94, 95% CI:
2.23 to 10.96; p < 0.0001). On multivariable analyses,ecade of Age
TABLE 2 Predictors of Recurrent Ischemic Neurologic Events
Univariable
HR (95% CI) p Value
Multivariable
HR (95% CI) p Value
Device closure 0.81 (0.47–1.40) 0.45
Age/yrs 1.01 (0.98–1.04) 0.40
Male 1.49 (0.86–2.69) 0.15
BMI/kg/m2 1.05 (1.00–1.09) 0.033
Diabetes mellitus 2.88 (1.45–5.74) 0.0027 3.39 (1.69–6.84) 0.0007
Hypertension 1.92 (1.11–3.31) 0.019
Ischemic heart disease 4.38 (1.07–18.01) 0.04
Cigarette smoking 1.68 (0.94–3.04) 0.08
Index TIA (vs. stroke) 1.98 (1.14–3.43) 0.015 2.13 (1.20–3.80) 0.010
Detection of AF 4.94 (2.23–10.96) <0.0001 4.85 (2.05–11.47) 0.0003
AF ¼ atrial ﬁbrillation or ﬂutter; CI ¼ conﬁdence interval; HR ¼ hazard ratio; other abbreviations
as in Table 1.
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917history of diabetes (HR: 3.39, 95% CI: 1.69 to 6.84;
p ¼ 0.0007), index TIA (HR: 2.13, 95% CI: 1.20 to 3.80;
p ¼ 0.01), and the detection of AF (HR: 4.85, 95% CI:
2.05 to 11.47; p ¼ 0.0003) independently predicted
recurrent ischemic neurologic events.
Separate models were built to identify predictors
of recurrent TIA and of recurrent stroke (Table 3). A
history of diabetes (HR: 5.54, 95% CI: 2.27 to 13.57;
p ¼ 0.0002) and detection of AF (HR: 7.29, 95% CI:
2.46 to 21.61; p ¼ 0.0003) independently predicted
recurrent ischemic strokes; whereas only index TIA
(HR: 4.71, 95% CI: 2.16 to 10.30; p ¼ 0.0001) was
associated with recurrent TIA.
ASSOCIATION OF THE ROPE SCORE WITH RECURRENT
NEUROLOGICAL EVENTS. The distribution of RoPE
scores within the CLOSURE I study is depicted in
Figure 2. A RoPE score of >5 was noted in 778 (85.6%)
patients. The RoPE score was associated with rates of
recurrent neurologic events such that 14.5% (19 of 131)
of subjects with a RoPE score #5 suffered a recurrent
event compared with 4.2% (33 of 778) of those with a
RoPE >5 (p < 0.0001) (Fig. 2).TABLE 3 Predictors of Recurrent Ischemic Strokes and TIA
Univariable
HR (95% CI) p Value
Multivariable
HR (95% CI) p Value
Stroke
BMI/kg/m2 1.06 (1.00–1.12) 0.057
Diabetes mellitus 4.76 (1.99–11.39) 0.0005 5.54 (2.27–13.57) 0.0002
Hypertension 1.74 (0.79–3.84) 0.17
Ischemic heart disease 9.09 (2.14–38.54) 0.0028
Index TIA (vs. stroke) 0.65 (0.24–1.73) 0.39
Detection of AF 7.79 (2.93–20.77) <0.0001 7.29 (2.46–21.61) 0.0003
TIA
BMI/kg/m2 1.04 (0.98–1.10) 0.19
Diabetes mellitus 1.83 (0.64–5.24) 0.26
Hypertension 1.95 (0.95–4.00) 0.07
Ischemic heart disease 3.78 (0.51–27.73) 0.19
Index TIA (vs. stroke) 4.66 (2.22–9.80) <0.0001 4.71 (2.16–10.30) 0.0001
Development of AF 2.08 (0.50–8.72) 0.32
Abbreviations as in Tables 1 and 2.DISCUSSION
The present analysis identiﬁed an association be-
tween several cardiovascular risk factors and recur-
rent neurologic events within the CLOSURE I trial.
Speciﬁcally, increased body mass index, diabetes,
hypertension, and ischemic heart disease predict
recurrent events, but among these, only diabetes was
an independent predictor of recurrent neurologic
events. Patients whose qualifying event was a TIA
(vs. ischemic stroke) and those in whom AF was
diagnosed after study enrollment were also at
increased risk of experiencing recurrent neurologic
events. Subgroup analyses further identiﬁed diabetes
and AF to be independent predictors of recurrent
stroke; whereas, an index TIA portended an increased
risk of recurrent TIA. Together, these data suggest
that a substantial proportion of recurrent events
within the CLOSURE I trial were not due to para-
doxical embolization.
Paradoxical embolization via a PFO may be impli-
cated as a cause of stroke in the absence of alternative
identiﬁable cause. To what degree stroke can be
attributed to PFO in this setting is a matter of debate.
Within the CLOSURE I, clinically signiﬁcant carotid
artery stenosis, complex aortic arch atheroma, or other
sources of cardioembolic phenomenon served as
exclusion criteria. Whereas causality cannot be deﬁn-
itively determined, the association of cardiovascular
risk factors such as diabetes with recurrent eventswithin this analysis implies that subclinical athero-
sclerosis and noncardioembolic causes of neurologic
events may have been present in many patients pre-
sumed to have had PFO-mediated events.
The RoPE score reﬂects the probability that a
discovered PFO is likely to be stroke-related and not
incidental (high scores). We found a broad distribu-
tion of RoPE scores within trial participants; however,
only 14% of patients had RoPE scores #5, indicating
that the inclusion criteria for the CLOSURE I trial were
largely effective in identifying patients with PFO-
mediated index events. However, in these 14% of
patients with low scores, the likelihood of PFO-
mediated stroke is low, ranging from 0 to 34% (35).
Moreover, over one-third of recurrent neurologic
events occurred within this subset of patients,
lending additional support to the notion that a sub-
stantial proportion (37%) of recurrent events within
FIGURE 2 RoPE Score Within the CLOSURE I trial
The prevalence of each RoPE (Risk of Paradoxical Embolism) score (0 through 10) within trial participants is depicted (blue line), superimposed
on the proportion of patients within each score category suffering a recurrent neurologic event (red bars). The risk of recurrent events increases
with decreasing RoPE score (p < 0.0001). Estimations for the PFO-attributable fraction, deﬁned as the estimated proportion of cryptogenic
strokes that are PFO-related, and the estimated 2-year recurrence rate of ischemic neurologic events based on corresponding RoPE score are
listed for reference (35). CLOSURE I ¼ Evaluation of the STARFlex Septal Closure System in Patients With a Stroke and/or Transient Ischemic
Attack Due to Presumed Paradoxical Embolism Through a Patent Foramen Ovale.
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918CLOSURE I were unlikely PFO-related. Should
percutaneous closure become available, patient se-
lection might be improved by more stringently
considering the burden of conventional vascular risk
factors that to a large degree drive the RoPE score.
Additional trials may be required to demonstrate
treatment efﬁcacy in this more focused population
(e.g., excluding patients with lower RoPE scores).
We found that the diagnosis of AF was the strongest
predictor of recurrent neurologic events, further sup-
porting concerns that recurrent events within
CLOSURE I were not PFO-mediated. Occult AF is
common in patients with cryptogenic neurologic
events (36,37). However, the distribution of occult
paroxysmal AF should equally distribute across treat-
ment arms with randomization; whereas, the rate of
AF was more than 8 greater in the device closure arm
than in the medical therapy arm within the CLOSURE I
trial (38). Such imbalance suggests that the closure
procedure or the NMT STARFlex device induce AF, as
has been suggested previously (39). This device- and
trial-speciﬁc ﬁnding may also help to explain the high
event rates in CLOSURE I compared with rates of other
PFO randomized controlled trials (31).
The causal mechanisms responsible for ischemic
stroke and for TIA are largely shared. It was conse-
quently surprising that an index TIA (vs. stroke) wouldportend an increased risk of recurrent events. Further
analysis revealed that index TIA was associated with
recurrent TIA, not recurrent stroke. Transient
ischemic attack is a nonspeciﬁc diagnosis that is often
assigned to amyriad of transient neurologic symptoms
(38,40,41). Moreover, disorders mimicking TIA, such
as epileptic seizure and migraine, are known to recur.
The CLOSURE I trial employed a rigorous deﬁnition of
TIA with adjudication of neurologic events after
enrollment. Nonetheless, our ﬁndings suggest that the
relative lack of speciﬁcity of TIA affected patient
enrollment as well as adjudication of recurrent
neurologic events within CLOSURE I. The inclusion of
imaging negative TIA within inclusion criteria and
endpoint deﬁnitions in CLOSURE I may further
explain the high rate of recurrence when compared
with rates of recurrence in the RESPECT (Randomized
Evaluation of Recurrent Stroke Comparing PFO
Closure to Established Current Standard of Care
Treatment) trial, in which TIA was not considered, and
the PC-Trial (Clinical Trial Comparing Percutaneous
Closure of Patent Foramen Ovale Using the Amplatzer
PFO Occluder with Medical Treatment in Patients with
Cryptogenic Embolism), which included clinical TIA
only in the presence of a “neuroradiologically veriﬁed
cerebral ischemic lesion” (32,33). The apparent lack of
speciﬁcity of the TIA diagnosis in the absence of
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919positive neuroimaging has signiﬁcant implications not
only for future PFO trials, but also for studies of other
cardioembolic phenomena and perhaps all trials in
which cerebrovascular events serve as an endpoint.
Rigorous measures are necessary to ensure that TIA
mimics are not used to justify trial entry and are not
adjudicated as neurologic events.
Together our ﬁndings emphasize the need for
clearer deﬁnitions and more stringent evaluation of
patients with suspected paradoxical embolism, not
only within clinical trials, but also in routine clinical
care. In addition, they highlight the need to imple-
ment comprehensive secondary prevention strategies
when managing patients with suspected paradoxical
embolism. Whereas the presence of cardiovascular
risk factors suggests an atherosclerosis-mediated
neurologic event, true causation often cannot be
determined, and such patients may certainly experi-
ence paradoxical embolism. The RoPE score adds to
our armamentarium for identifying PFO-mediated
stroke; similar efforts are needed to distinguish TIA
from TIA mimics. The emergence of diffusion-
weighted magnetic resonance neuroimaging has
partially ﬁlled this need (42), but additional criteria
are needed to help identify TIA due to paradoxical
embolism.
STUDY LIMITATIONS. First, the number of recurrent
neurologic events within the CLOSURE I trial, and
hence statistical power to identify independent
predictors of recurrent events was limited. Second,
the prevalence of diabetes and incidence of AF may
each be underestimated as their occurrence was not
systematically collected within the CLOSURE I trial.
The magnitude of association between these factors
and recurrent events may consequently be over-
estimated. Third, data from the device closure and
medical therapy arms of the CLOSURE I trial were
pooled for this analysis, eliminating the possibility
of identifying PFO-related predictors of recurrent
neurologic events. Similarly, device-related factors,
such as residual shunt or device-related thrombus,were not evaluated, although none of the recurrent
neurologic events occurred in patients with residual
shunt. Fourth, we used the RoPE score to gauge the
PFO-attributable risk within the CLOSURE I trial
cohort. Whereas the RoPE score effectively gener-
ates strata of cryptogenic stroke, patients with
greatly different PFO prevalences and therefore
different PFO-attributable risks, as with most risk
prediction models, it is not comprehensive of all
potentially relevant factors and cannot be used in
exclusion of clinical judgment. Finally, it is impor-
tant to note that the identiﬁed risk factors for
recurrent neurologic events represent statistical as-
sociations and that inference of causal mechanisms
should be done with caution, if at all. Despite these
limitations, our analysis provides valuable insights
into the results of the CLOSURE I trial and for the
clinical management of patients with suspected
paradoxical embolism.CONCLUSIONS
Within the CLOSURE I trial, several atherosclerotic
risk factors, including increased body mass index,
diabetes, hypertension, and history of ischemic heart
disease predicted recurrent ischemic neurologic
events. However, a diagnosis of AF after trial enroll-
ment portended the greatest risk of recurrent events.
An increased risk of recurrent TIA, but not stroke, was
present in those patients whose qualifying event was
a TIA. Together, these data support an alternative
etiology to paradoxical embolization for many of the
observed recurrent ischemic neurologic events within
the CLOSURE I trial and emphasize the challenges
inherent in managing patients with PFO and crypto-
genic stroke.
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